skip to main content
Back to Top

The COVID-19 Resource Canada Site

Funding opportunities

The Science | Business Repository of COVID-19 Related

Funding opportunities


Public Health Agency of Canada | Preventing and addressing family violence

Letter of Intent deadline: January 27, 2021
Funding available: Minimum $100,000 annually. No maximum budget per project. Anticipated support is for up to 30 projects with funding envelope of up to $6,000,000 per year. Project length can be from two to four years.

The Public Health Agency of Canada (PHAC) is pleased to invite eligible organizations to submit a Letter of Intent (LOI) for projects that prevent and address family violence and its health impacts by delivering, testing and supporting diverse health promotion programs and interventions that are tailored to the needs of those who have experienced, are experiencing, or are at-risk of experiencing family violence. 

More information


Parkinson Canada 2021

Application deadline: February 1, 2021
Funding available: 
Graduate Studentship Award: Two-year duration $10,000 per year
Basic Research Fellowship: Two-year duration $40,000-$50,000 per year
Clinical Movement Disorders Fellowship: One-year duration $50,000
Clinical Research Fellowship: Two-year duration $50,000 per year

The Parkinson Canada Research Program funds research into the cure, cause, progression, improved treatment and/or understanding of Parkinson's disease, related disorders including Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), other Parkinson's conditions and the impact these diseases have on society. 

More information


SSHRC Connection Grant – Winter

Application deadline: February 1, 2021
Funding available: Events: $7,000 to $25,000; Outreach activities: $7,000 to $50,000; higher amounts may be considered if well justified

SSHRC Connection Grant is meant to support workshops, colloquiums, conferences, forums, etc., that facilitate disciplinary and/or interdisciplinary exchanges in the humanities and social sciences; and scholarly exchanges between those working in the social sciences and humanities and those working in other research fields sectors and industries.

More information


Alzheimer’s Drug Discovery Foundation Neuroimaging and CSF Biomarker Development Program

Letter of intent deadline: February 5, 2021; May 28, 2021; October 1, 2021
Funding available: Up to $600,000 based on stage and scope of research, per year. One year with potential for follow-on funding. Multi-year proposals can be considered.

More information


Alzheimer’s Drug Discovery Foundation Drug Development Program

Letter of intent deadline: February 5, 2021; May 28, 2021; October 1, 2021
Funding available: Up to $600,000 based on stage and scope of research, per year. One year with potential for follow-on funding. Multi-year proposals can be considered.

The Drug Development RFP seeks to support in vivo preclinical studies that advance lead molecules developed for Alzheimer’s disease and related dementias to IND-enabling studies. The proposed studies should be structured to deliver a compound with strong potential for clinical and commercial application. This funding opportunity prioritizes novel drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP. 

More information


Alzheimer’s Drug Discovery Foundation Program to Accelerate Clinical Trials (PACT)

Letter of intent deadline: February 5, 2021; May 28, 2021; October 1, 2021
Funding available: Up to $3,000,000 based on stage and scope of research. For studies requiring additional support, co-funding from other funding agencies or investors is encouraged. Payment structure will be negotiated and based on milestone achievements and recruitment. Average duration multi-year, with potential for follow-on funding.

The PACT RFP supports IND-enabling studies and early-phase clinical trials that test promising pharmacological interventions and devices for Alzheimer’s disease (AD) and related dementias. Both disease-modifying and symptomatic agents will be considered. This funding opportunity prioritizes diverse drug mechanisms and modes of action related to the biology of aging and other emerging therapeutic areas for dementia. For this reason, amyloid targeted approaches and cholinesterase inhibitor proposals will not be considered for this RFP. 

More information


Alzheimer's Drug Discovery Foundation Prevention Pipeline

Letter of intent deadline: February 5, 2021; May 28, 2021; October 1, 2021
Funding available: Up to 3,000,000 for clinical trials based on stage and scope of research. Multi-year with potential for follow-on funding.

The Prevention Pipeline RFP supports studies of cognitive decline and risk reduction, comparative effectiveness research, studies leveraging the consortium of Cohorts for Alzheimer’s Prevention Action (CAPA).

More information


NIA Novel Mechanism Research on Neuropsychiatric Symptoms in Alzheimer's Dementia (R01 Clinical Trial Optional)

Application deadline: February 5, 2021
Funding available: Application budgets are not limited but need to reflect proposed project needs

The goal of this call is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms in persons with Alzheimer's disease or Alzheimer's disease-related dementias. This call uses the R01 mechanism, while the companion call PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism. 

More information


NIH Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required)

Application deadline: February 5, 2021
Funding available: See award

More information


NIA Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R21 Clinical Trial Optional)

Application deadline: February 16, 2021
Funding available: The combined budget for direct costs for the two-year project period may not exceed $275,000, and no more than $200,000 may be requested in any single year

This call is to encourage applications for studies that will enhance knowledge of mechanisms associated with neuropsychiatric symptoms in persons with Alzheimer's disease or Alzheimer's disease-related dementia. PAR-20-157 uses the R01 grant mechanism, while PAR-20-159 uses the R21 mechanism. High risk/high payoff projects that lack preliminary data or utilize existing data may be most appropriate for the R21 mechanism.

More information


CIHR | Training Grant: CIHR-NSERC-SSHRC Healthy Cities Research Training Platform

Application deadline: February 18, 2021
Funding available: $150,000 is available to fund up to six (6) developmental grants up to $25,000 per grant. $4,950,000 is available for the Full Application which is enough to fund one (1) grant. This amount may increase if additional funding partners participate. The maximum amount for the grant is $825,000 per year for up to six (6) years.

The goal of this funding opportunity is to deliver a national training initiative focused on building capacity among Canadian researchers to engage in high quality, impactful research on how to design, implement and scale innovative, solution-based interventions in a variety of urban contexts.

More information


CIHR | Health System Fellowship (Doctoral and Postdoctoral)

Application deadline: February 18, 2021
Funding available: Doctoral award = $50,000, Postdoctoral award = $155,000

The Health System Impact (HSI) Fellowship (for doctoral trainees and post-doctoral fellows) provides highly-qualified doctoral trainees and post-doctoral fellows studying health services and policy research, or related fields, a unique opportunity to apply their research and analytic talents to critical challenges in health care that are being addressed by health system and related organizations (e.g., public, private for-profit, not-for-profit, and Indigenous health organizations that are not universities) outside of the traditional university setting, and to also develop professional experience, new skills, and networks. 

More information


Michael J. Fox Foundation for Parkinson’s Research | Analysis of patient-reported outcomes (PROs) from Fox Insight

Pre-proposals deadline: October 22, 2020 5 p.m. EST
Full proposal invitations: December 21, 2020
Full proposal due (by invite only): March 18, 2021, 5 p.m. EST
Funding available: Up to $100,000 for one-year grants

PROs collected in Fox Insight capture information on the lived experience of Parkinson’s that can transform therapeutic development, clinical care, and public policy for people with the disease. Data from tens of thousands of people with and without Parkinson’s participating in the study provides the necessary power to generate new understanding of a heterogeneous disease. Investigators unfamiliar with Parkinson’s who present compelling proposals for methods may be paired with a Parkinson’s expert for contextualizing analysis to clinical practice. The dataset and additional resources are available in the Fox Insight Data Exploration Network (Fox DEN).

More information


Michael J. Fox Foundation for Parkinson’s Research | Development and Validation of Improved Outcome Measures Analysis 

Pre-proposals deadline: October 22, 2020 5 p.m. EST
Full proposal invitations: December 21, 2020
Full proposal due (by invite only): March 18, 2021, 5 p.m. EST
Funding available: Up to $750,000 for two years

The Michael J. Fox Foundation (MJFF) seeks applications to develop objective biomarkers that can support therapeutic development in Parkinson’s. These may include biomarkers that improve definitive diagnosis, objectively track disease progression, enrich for subject populations, or more precisely detect a treatment response or target engagement. The availability of these types of biomarkers would transform clinical trial design and assist in the interpretation of trial results.

More information 


Michael J. Fox Foundation for Parkinson’s Research | PIPETTE: 4R tau and alpha-synuclein PET tracer development

Pre-proposals deadline: October 22, 2020 5 p.m. EST
Full proposal invitations: December 21, 2020
Full proposal due (by invite only): March 18, 2021, 5 p.m. EST
Funding available: Total funding available is $1 million

The PIPETTE Consortium (Philanthropic Investments in PET TracErs) is a funding partnership formed in 2017 by The Michael J. Fox Foundation and Rainwater Charitable Foundation (conveners of the Tau Consortium). The partnership’s goal is to accelerate the development of novel 4R tau and alpha-synuclein PET tracers for primary non-Alzheimer’s tauopathies, Parkinson’s disease, Lewy body dementia, frontotemporal dementia, and other neurodegenerative diseases. As a collaborative effort of leading non-profit organizations, the PIPETTE Consortium seeks to pool ideas, expertise, and resources to enable improved diagnosis and treatment of multiple disorders.

More information


Michael J. Fox Foundation for Parkinson’s Research | Target advancement program

Pre-proposals deadline: October 22, 2020 5 p.m. EST
Full proposal invitations: December 21, 2020
Full proposal due (by invite only): March 18, 2021, 5 p.m. EST
Funding available: Up to $150,000 for 18 to 24 months

The Michael J. Fox Foundation believes that promoting target and pathway validation studies within academic and industry laboratories can bridge the critical gap between basic biology and therapeutic development. Validation efforts should focus on early-stage targets that have previously been implicated in Parkinson’s but have not yet been rigorously tested for their ability to impact disease-relevant outcomes in Parkinson's model systems. Submitted projects should investigate whether genetic or pharmacological modulation of the target can affect Parkinson's-relevant biological pathways or phenotypes in model systems that may be predictive of therapeutic efficacy.

More information


Michael J. Fox Foundation for Parkinson’s Research | Therapeutic pipeline program

Pre-proposals deadline: October 22, 2020 5 p.m. EST
Full proposal invitations: December 21, 2020
Full proposal due (by invite only): March 18, 2021, 5 p.m. EST
Funding available: Up to $500,000 for one- to two-year pre-clinical grants; Up to $2 million for two- to three-year clinicals grants

The Michael J. Fox Foundation seeks applications with potential for fundamentally altering disease course and/or significantly improving treatment of symptoms above and beyond current standards of care. The Therapeutic Pipeline Program is open to industry and academic investigators proposing novel approaches or repositioning approved or clinically safe therapies from other disease indications.

More information


Alzheimer Society Brant, Haldimand, Norfolk, Hamilton, Halton | Research Grant Application

Application deadline: April 1, 2021; October 15, 2021
Funding available: The Alzheimer Society will consider applications for both monetary and non-monetary research support. Funds will be distributed through three distinct categories: research (max $15000), publication (max $2000) and, travel (max $1000)

More information


Aligning Science Across Parkinson’s (ASAP) – Collaborative Research Network

Pre-proposal deadline: December 11, 2020
Full application: 
April 13, 2021
​Funding ​Available: Up to $9,000,000 over three years, per team (additional funding available for pre-clinical models)

The ASAP initiative is accepting applications to support multidisciplinary research teams to join the newly established ASAP Collaborative Research Network. ASAP seeks to fund research projects that address key knowledge gaps in the basic mechanisms that contribute to Parkinson’s development and progression. Applications that focus primarily on circuitry and brain-body interactions, inclusive of genetic and neuro-immune contributors to disease, will be considered.

More information


The W. Garfield Weston Foundation Brain Health 2021: Lifestyle approaches and microbiome contributions

Letter of intent deadline: November 25, 2020
Proposal deadline: April 15, 2021
Funding available: Up to $1.5 million per project up to three years

The program seeks to increase the number of Canadians maintaining better brain health throughout their lives. This program aims to advance the treatment (e.g., symptomatic relief, disease modification) and/or prevention of neurodegenerative diseases of aging by accelerating the development and implementation of lifestyle approaches and/or identifying the contribution of the microbiome.

More information


NIH Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)

Application deadline: May 7, 2021
Funding available: See award

More information


NIH Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)

Application deadline: May 7, 2021
Funding available: See award

More information


Active and Assisted Living Programme Call for Proposals 2021: Advancing inclusive health & care solutions for ageing well in the new decade

Application deadline: May 21, 2021
Funding available: Collaborative projects (carried out by consortia composed of at least 3 organizations from 3 different countries including an end user organization and a business partner) will remain the main funding tool for this call. This type of projects has a duration of 12 to 30 months with a maximum funding of €2.500.000. Small collaborative projects have a duration of 6 to 9 months, the same central eligibility criteria as the Collaborative projects, a maximum co-funding budget of €300.000 and leaner application and reporting procedures.

Digital solutions in health and care can support the well-being of older adults in many areas of their daily lives at home and in their communities. They can also support care professionals and informal carers and help tap into the labour potential of active and healthy older people. While keeping an open call approach, the call 2021 would like to stress an inclusive health and care approach (health prevention, preservation of physical and mental health, social participation), the stimulation and upscaling of innovation in active and healthy aging through health and care eco-systems and the accessibility of digital solutions to end users, e.g., through education for greater e-literacy.

More information


CIHR | Team Grant: Indigenous Healthy Life Trajectories Initiative Cohort Research Study (I-HeLTI)

Application deadline: June 9, 2021
Funding available: The total amount available for this funding opportunity is $14,100,000

More information


CIHR | Team Grant: Diabetes Mechanisms and Translational Solutions

Application deadline: July 13, 2021
Funding available: The maximum amount per grant is $400,000 per year for up to 5 years, for a total up to of $2,000,000 per grant.

As part of 100 Years of Insulin: Accelerating Canadian Discoveries to Defeat Diabetes, the Team Grants in Diabetes Mechanisms and Translational Solutions will support multi-disciplinary research to better understand the underlying causes and pathophysiology of diabetes and develop improved prevention and treatment approaches for diabetes. For the purposes of this Initiative, diabetes includes all forms of diabetes mellitus, its complications, and co-morbidities. Mechanistic research is defined as studies designed to understand the pathophysiology of diabetes, its complications, and co-morbidities. Translational research is defined as research that advances effective translation and application of knowledge across the expanse of pre-clinical, clinical and health services delivery domains to improve patient outcomes.

More information


CIHR Institute of Aging| Planning and Dissemination Grants

Application deadline: December 13, 2021
Funding available: The maximum amount awarded for a single grant is $25,000.

More information


Alzheimer’s Drug Discovery Foundation Diagnostics Accelerator: Digital Biomarkers

Application deadline: Rolling
Funding available:
Exploratory: Up to $250,000
Proof-of-principle up to $500,000
Validation: Based on stage and scope of research

More information


Alzheimer's Drug Discovery Foundation: Diagnostics Accelerator: Peripheral Biomarkers Program

Application deadline: Rolling
Funding available:
Exploratory: Up to $250,000
Proof-of-principle up to $500,000
Validation: Based on stage and scope of research

Diagnostics Accelerator is a partnership of funders dedicated to accelerating the development of affordable and accessible peripheral biomarkers to diagnose Alzheimer's disease and related dementias, and to advance the development of personalised medicine. Through translational research awards and access to consulting support from industry experts, this program will challenge the research community to develop novel biomarkers from peripheral modalities. Peripherally-sourced biomarkers will enable greater patient tolerability, integration with existing sample testing infrastructure, and the scalability and affordability necessary for population-level screening. 

More information


Birks Family Foundation Grant

Application deadline: Rolling (apply six months prior to when funds would be required) 
Funding available: Application dependent

The Birks Family Foundation funds organizations either primarily focused on Quebec, or those whose work is broadly national in nature; Public sector organizations, including universities, hospitals, libraries and museums; Projects that demonstrate unique innovation in their field and/or pioneer state-of-the-art technology; Long range projects designed to become self-sustaining; and, organizations that actively engage directly with their target group through programs and/or services. 

More information


Dementia Consortium

Application deadlines: Expression of Interest is reviewed every two months, while full applications (invitation only) are reviewed every three months. Check the website for the next deadline
Funding available: £100,000 to £250,000 (£500,000 for exceptional cases)

The consortium brings together publicly backed funders of medical research, experts in scientific assessment, and the scale and strength of industry to support the development of promising research. The consortium seeks promising research from academia and considers appropriate funding and development routes. Once complete, successful projects may be moved towards the clinic by industry, and all parties share in the success.

More information


Max Bell Foundation Grant

Application deadline: Rolling
Funding details: Apply for the amount of money that you need to complete your project. Be aware that Max Bell Foundations generally funds 30-60% of a project and prefers to fund projects that have other funders.

The foundation prefers to collaborate with applicants to create final project proposals. Proposals should focus on development of forward-looking innovations that impact public policies and practices with an emphasis on health and wellness, education, and the environment.

More information


NSERC Alliance

Application deadline: applications are currently being accepted for Option 1 and 2
Funding available: $20,000 to $1,000,000 per year for one to five years

NSERC Alliance grants encourage university researchers to collaborate with partner organizations, which can be from the private, public or not-for-profit sectors. Funding may support research and development projects that seek to respond to a research challenge in the natural sciences or engineering, while working with external partners who are able to accelerate scale-up, application, impact, or commercialization. NSERC is now accepting Option 1 applications requiring at least 50 per cent matching cash contributions from partner organizations, and for Option 2, involving non-profit partners and requesting 90 to 100 per cent funding support from NSERC.

More information


Physician’s Services Incorporated (PSI) Foundation 

Clinical Research Grant

The PSI Clinical Research Grant is open to Post M.D. physicians looking to conduct research which is of direct relevance to patient care.

Health Systems Research Grant

The Health Systems research grant funds projects of a special nature within the healthcare system, such as preventative medicine, care of the elderly, communications within the system, underserviced regions, and ways of enhancing the effectiveness of medical practice will be considered under this category. 

More information

New Investigator Research Grant 

The New Investigator funding stream is open to Clinical Fellows or physicians within five years of their first academic appointment. 

More information

Resident Research Grant 

Resident Research Grants are concise health research projects, which have been largely developed by the Resident. To be eligible to apply for a Resident Research Grant, the Resident must have PGY status as per the College of Physicians and Surgeons of Ontario. The restriction whereby PSI will not consider applications for research within the areas of cancer, and heart and stroke does not apply to resident research projects.

More information

Healthcare Research by Community Physicians Grant 

To assist physicians practicing in a community setting to undertake a review of their practice patterns which would enhance effectiveness of practice and patient care in their own clinic, hospital, or region.

More information

Graham Farquharson Knowledge Translation Fellowship 

The PSI Graham Farquharson Fellowship is intended to provide salary support for a new investigator who has demonstrated the ability to successfully complete high impact knowledge translation research. The Fellowship funds, dedicated to salary support, must protect at least 50% of the Fellow’s time to conduct such research.

More information


The W. Garfield Weston Foundation: Early Phase Clinical Trials

Letter of intent deadline: Rolling
Funding available: Up to $1.5 million per project up to four years

Neurodegenerative diseases of aging are among the least understood and most undertreated diseases today. Diseases such as Alzheimer’s and Parkinson’s are placing a large and increasing burden on society. If ignored, the social and economic costs of managing these diseases will rise significantly within a generation. Meeting these challenges requires pioneering approaches to accelerating treatments. The Early Phase Clinical Trials: Canada program was created to provide funding support for clinical trials and clinical trial sub-studies with excellent preliminary data. 

More information

Email MIRA at: MIRAinfo@mcmaster.ca       Follow us on Twitter : @MIRAMcMaster
McMaster Footer Logo
Institute For Research On Aging Footer Logo

© 201​6 McMaster University  |  MIP Suite 109A, 1280 Main St. W., Hamilton, ON L8S 4K1  |  Contact Us  | Email UsTerms of Use & Privacy Policy